Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Adiponectin, an insulin-sensitizing factor secreted from adipose tissue, is decreased in individuals with type 2 diabetes (T2D) and increased in response to thiazolidinedione (TZD) therapy. Changes in its secretion and assembly into higher-order forms affect insulin sensitivity. To determine the relative potency of TZDs on intra-adipocyte multimerization and secretion of adiponectin, we assessed the impact of in vivo low- or high-dose rosiglitazone treatment alone or combined with metformin in subjects with T2D. T2D subjects received high-dose rosiglitazone (8 mg/day), high-dose metformin (2,000 mg/day), or low-dose combination rosiglitazone-metformin therapy (4 mg + 1,000 mg/day) for 4 mo. All subjects were then switched to high-dose rosiglitazone-metformin combination therapy (8 mg + 2,000 mg/day) for another 4 mo. Low-dose rosiglitazone increased serum adiponectin, whereas the high dose increased both adipocyte content and serum adiponectin levels. TZDs selectively increased the percentage of circulating adiponectin in the potent, high-molecular-weight (HMW) form. No TZD effects were evident on multimer distribution in the cell. Expression of the chaperone protein ERp44, which retains adiponectin within the cell, was decreased by TZD treatment. No changes occurred in Ero1-Lα expression. Metformin had no effect on any of these measures. Increases in adiponectin correlated with improvements in insulin sensitivity. In vivo, TZDs have apparent dose-dependent effects on cellular and secreted adiponectin. TZD-mediated improvements in whole body insulin sensitivity are associated with increases in circulating but not cellular levels of the HMW adiponectin multimer. Finally, TZDs promote the selective secretion of HMW adiponectin, potentially, in part, through decreasing the expression of the adiponectin-retaining protein ERp44.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cnop, M., Havel, P. J., Utzschneider, K. M., Carr, D. B., Sinha, M. K., Boyko, E. J., Retzlaff, B. M., Knopp, R. H., Brunzell, J. D., & Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-003-1074-z · Cited by 1,483
Pajvani, U. B., Hawkins, M., Combs, T. P., Rajala, M. W., Doebber, T., Berger, J. P., Wagner, J. A., Wu, M., Knopps, A., Xiang, A. H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311113200 · Cited by 1,163
Hotta, K., Funahashi, T., Bodkin, N. L., Ortmeyer, H. K., Arita, Y., Hansen, B. C., & Matsuzawa, Y. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1126 · Cited by 1,072
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524 · cited 1×
“In agreement with previous reports (32), we found that the TZD rosiglitazone increased serum adiponectin levels in type 2 diabetic subjects and that this increase correlated with an improvement in insulin sensitivity as measured by the glucose disposal rate during a hyperinsulinemic euglycemic clamp (24).”
ResultSecretory factors from human adipose tissue and their functional role
Hauner, H. (2005) · Proceedings of the Nutrition Society · doi:10.1079/pns2005428 · Cited by 391 · cited 1×
“AS THE PREVALENCE OF OBESITY CONTINUES to rise at an alarming rate, so do associated rates of obesity-related metabolic dysfunction; among these are coagulation abnormalities, dyslipidemia, hyperinsulinemia, glucose intolerance, and type 2 diabetes (13, 34).”
Background
Cited by
Adipose tissue as an endocrine organ
Galic, S., Oakhill, J. S., & Steinberg, G. R. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.08.018 · Cited by 1,562
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis
Green, C. R., Wallace, M., Divakaruni, A. S., Phillips, S. A., Murphy, A. N., Ciaraldi, T. P., & Metallo, C. M. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1961 · Cited by 471
Self-citationRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Adiponectin and cardiovascular health: an update
Hui, X., Lam, K. S., Vanhoutte, P. M., & Xu, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01395.x · Cited by 286
Metadata
- Authors
- Phillips, S. A., Kung, J., Ciaraldi, T. P., Choe, C., Christiansen, L., Mudaliar, S., & Henry, R. R.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2009-09
- Volume
- 297
- Issue
- 3
- Pages
- E767-E773
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2166094127
- Cited by
- 53
- References
- 6
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. https://app.cochat.ai/papers/10.1152/ajpendo.00378.2009
- The paper
- Phillips, S. A., Kung, J., Ciaraldi, T. P., Choe, C., Christiansen, L., Mudaliar, S., & Henry, R. R. (2009). Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00378.2009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.